Ressources

On January 27 to 28, 2025, the Ontario Drug Policy Research Network (ODPRN) hosted a Community Substance Use Forum, “Together for Change”.

This is a report from the government of Canada highlighting the emergence of Xylazine in the unregulated drug supply. 

This evaluation report explores the implementation and impacts of the Prescribed Alternatives and Outreach (PAO) program at the Hamilton Urban Core Community Health Centre.

Severe opioid withdrawal, risk of patient-initiated discharge, and some inpatients’ use of unregulated substances prompt clinical and ethical questions considered in this commentary on a case.&nbsp

This report aims to provide the results of the program evaluation of the safer supply pilot program in Thunder Bay, ON from October 2022 to March 2024.

This report focuses on participant experiences of the Peterborough Safer Supply Program (SSP ).

This Health Canada funded project is called “Embedding a Safer Supply Program (SSP) in a Smaller Urban Community” and represents a unique opportunity to pilot Safer Supply in a small city of approx

This report presents an overview of the Safer Supply Ottawa program, as well as the results of a Safer Stimulant Supply program evaluation conducted in the spring and summer of 2024.

This study aimed to quantify self-stigma, explore some aspects of perceived stigma, determine the factors associated with greater self-stigma and examine whether the level of self-stigma was relate

Identifying the most effective state laws and provisions to reduce opioid overdose deaths remains critical.

Infrastructural violence ensues when infrastructure is designed for some members or groups within a society while perpetuating violence among others.

This research examines how nurses' talk and institutional texts discursively construct social justice within the institutional context of the emergency department, and how such discourses shape the

This study sought to understand the specific characteristics and operations of harm reduction housing (HRH) in Boston to generate a comprehensive inventory tool for evaluating implementation of har

To assess real-world access to buprenorphine treatment in Philadelphia and measure adoption of policies and practices that facilitate buprenorphine access.

This commentary is concerned with buprenorphine treatment for individuals with opioid use disorder in the fentanyl era.

The rise of high-potency opioids such as fentanyl makes buprenorphine initiation challenging due to the risks of precipitated withdrawal, prompting the exploration of strategies, such as low-dose i